en
Conference presentation
Open access
English

LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial

Presented atESMO Congress 2022, Paris, 9-13 september 2022
Publication date2022-09
NotePublié dans : Annals of Oncology, 2022, 33(S7) : S1429
Citation (ISO format)
ROTHERMUNDT, C.a. et al. LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial. In: ESMO Congress 2022. Paris. 2022. doi: 10.1016/j.annonc.2022.08.068
Main files (1)
Presentation
Identifiers
12views
1downloads

Technical informations

Creation12/06/2023 1:37:51 PM
First validation04/03/2024 7:48:31 AM
Update time04/03/2024 8:15:07 AM
Status update04/03/2024 8:15:07 AM
Last indexation04/03/2024 8:15:09 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack